Relmada Therapeutics (RLMD) Free Cash Flow (2012 - 2026)
Relmada Therapeutics (RLMD) reported Free Cash Flow of -$15.1 million for Q1 2026, up 16.6% year-over-year from -$12.9 million in Q1 2025, and down 3.23% on a QoQ basis from -$14.6 million in Q4 2025.
Relmada Therapeutics (RLMD) has 15 years of Free Cash Flow data on file, last reported at -$15.1 million in Q1 2026.
- Quarterly Free Cash Flow rose 16.6% year-over-year to -$15.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$42.8 million (up 24.65% YoY) and the FY2025 annual result came in at -$45.8 million, up 11.53% from the prior year.
- Free Cash Flow fell to -$15.1 million in Q1 2026 per RLMD's latest filing, from -$14.6 million in the prior quarter.
- Across five years, Free Cash Flow topped out at -$6.4 million in Q2 2025 and bottomed at -$35.9 million in Q4 2022.
- The 5-year median for Free Cash Flow is -$14.6 million (2025), against an average of -$15.8 million.
- The widest annual swing landed in 2023, when Free Cash Flow jumped 71.44%; it then slumped 65.87% in 2025.
- Tracing RLMD's Free Cash Flow over 5 years: stood at -$35.9 million in 2022, then jumped by 71.44% to -$10.2 million in 2023, then climbed by 14.15% to -$8.8 million in 2024, then plunged by 65.87% to -$14.6 million in 2025, then dropped by 3.23% to -$15.1 million in 2026.
- Per Business Quant, the three latest RLMD Free Cash Flow figures stand at -$15.1 million (Q1 2026), -$14.6 million (Q4 2025), and -$6.7 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -1.67 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -12.20 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -2.49 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 1.29 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 848.30 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 48.67 Mn |
| 10 | Relmada Therapeutics | 595.35 Mn | 595.35 Mn | - | -15.07 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -15.07 Mn |
| Mar 31, 2026 | -15.07 Mn |
| Dec 31, 2025 | -14.60 Mn |
| Dec 31, 2025 | -14.60 Mn |
| Sep 30, 2025 | -6.72 Mn |
| Sep 30, 2025 | -6.72 Mn |
| Jun 30, 2025 | -6.40 Mn |
| Jun 30, 2025 | -6.40 Mn |
| Mar 31, 2025 | -18.07 Mn |
| Mar 31, 2025 | -18.07 Mn |
| Dec 31, 2024 | -8.80 Mn |
| Dec 31, 2024 | -8.80 Mn |
| Sep 30, 2024 | -16.66 Mn |
| Sep 30, 2024 | -16.66 Mn |
| Jun 30, 2024 | -13.26 Mn |
| Jun 30, 2024 | -13.26 Mn |
| Mar 31, 2024 | -13.04 Mn |
| Mar 31, 2024 | -13.04 Mn |
| Dec 31, 2023 | -10.25 Mn |
| Dec 31, 2023 | -10.25 Mn |
| Sep 30, 2023 | -11.63 Mn |
| Sep 30, 2023 | -11.63 Mn |
| Jun 30, 2023 | -13.27 Mn |
| Jun 30, 2023 | -13.27 Mn |
| Mar 31, 2023 | -16.51 Mn |
| Mar 31, 2023 | -16.51 Mn |
| Dec 31, 2022 | -35.88 Mn |
| Dec 31, 2022 | -35.88 Mn |
| Sep 30, 2022 | -26.86 Mn |
| Sep 30, 2022 | -26.86 Mn |
| Jun 30, 2022 | -21.63 Mn |
| Jun 30, 2022 | -21.63 Mn |
| Mar 31, 2022 | -19.43 Mn |
| Mar 31, 2022 | -19.43 Mn |
| Dec 31, 2021 | -37.66 Mn |
| Dec 31, 2021 | -37.66 Mn |
| Sep 30, 2021 | -20.92 Mn |
| Sep 30, 2021 | -20.92 Mn |
| Jun 30, 2021 | -17.21 Mn |
| Jun 30, 2021 | -17.21 Mn |
| Mar 31, 2021 | -16.09 Mn |
| Mar 31, 2021 | -16.09 Mn |
| Dec 31, 2020 | -6.93 Mn |
| Dec 31, 2020 | -6.93 Mn |
| Sep 30, 2020 | -12.50 Mn |
| Sep 30, 2020 | -12.50 Mn |
| Jun 30, 2020 | -4.95 Mn |
| Jun 30, 2020 | -4.95 Mn |
| Mar 31, 2020 | -3.42 Mn |
| Mar 31, 2020 | -3.42 Mn |
| Dec 31, 2019 | -91.26 Mn |
| Dec 31, 2019 | -91.26 Mn |
| Sep 30, 2019 | -2.53 Mn |
| Sep 30, 2019 | -2.53 Mn |
| Jun 30, 2019 | -5.68 Mn |
| Jun 30, 2019 | -5.68 Mn |
| Mar 31, 2019 | -2.01 Mn |
| Mar 31, 2019 | -2.01 Mn |
| Dec 31, 2018 | 3.39 Mn |
| Dec 31, 2018 | 3.39 Mn |
| Sep 30, 2018 | -1.67 Mn |
| Sep 30, 2018 | -1.67 Mn |
| Jun 30, 2018 | -9,800.00 |
| Jun 30, 2018 | -9,800.00 |
| Mar 31, 2018 | -1.63 Mn |
| Mar 31, 2018 | -1.63 Mn |
| Dec 31, 2017 | -1.13 Mn |
| Dec 31, 2017 | -1.13 Mn |
| Sep 30, 2017 | -981,639.00 |
| Sep 30, 2017 | -981,639.00 |
| Jun 30, 2017 | -1.02 Mn |
| Jun 30, 2017 | -1.02 Mn |
| Mar 31, 2017 | -1.88 Mn |
| Mar 31, 2017 | -1.88 Mn |
| Dec 31, 2016 | -1.45 Mn |
| Dec 31, 2016 | -1.45 Mn |
| Sep 30, 2016 | -2.17 Mn |
| Sep 30, 2016 | -2.17 Mn |
| Jun 30, 2016 | -2.85 Mn |
| Jun 30, 2016 | -2.85 Mn |
| Mar 31, 2016 | -3.69 Mn |
| Mar 31, 2016 | -3.69 Mn |
| Dec 31, 2015 | -3.95 Mn |
| Dec 31, 2015 | -3.95 Mn |
| Sep 30, 2015 | -3.22 Mn |
| Sep 30, 2015 | -3.22 Mn |
| Jun 30, 2015 | -4.49 Mn |
| Jun 30, 2015 | -4.49 Mn |
| Mar 31, 2015 | -4.43 Mn |
| Mar 31, 2015 | -4.43 Mn |
| Dec 31, 2014 | -4.99 Mn |
| Dec 31, 2014 | -4.99 Mn |
| Sep 30, 2014 | -2.33 Mn |
| Sep 30, 2014 | -2.33 Mn |
| Jun 30, 2014 | -2.17 Mn |
| Jun 30, 2014 | -2.17 Mn |
| Mar 31, 2014 | -1.86 Mn |
| Mar 31, 2014 | -1.86 Mn |
| Nov 30, 2013 | -9,124.00 |
| Nov 30, 2013 | -9,124.00 |
| Feb 28, 2013 | -2,942.00 |
| Feb 28, 2013 | -2,942.00 |
| Nov 30, 2012 | 1,497.00 |
| Nov 30, 2012 | 1,497.00 |
| Aug 31, 2012 | -3,344.00 |
| Aug 31, 2012 | -3,344.00 |
| May 31, 2012 | -1,986.00 |
| May 31, 2012 | -1,986.00 |